Observational studyViruses2023

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.

José Luis Piñana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.